Companies: 10,795·Total market cap: $144.5T
Annovis Bio, Inc.

Annovis Bio, Inc.

ANVSNYSEHealthcare● Active
$1.82
+$0.03(+1.40%)
Market Cap$35707612
P/E Ratio
52W High$5.5
52W Low$1.54
Overview

Annovis Bio, Inc. (ANVS) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001477845 · ANVS · NYSE · as of Jun 9, 2026

Filing snapshot

297
Total Filings
4
Latest Form
2026-05-21
Most Recent
2020
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001477845 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-13
Fiscal Year End
Mar 13, 2026
Accession No.
0001104659-26-027751
Primary Document
anvs-20251231x10k.htm
Source: data.sec.gov · CIK 0001477845 · Accession 0001104659-26-027751

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-15
8-KCurrent Report
FORM 8-K
2026-05-20Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
8-KCurrent Report
FORM 8-K
2026-05-20
View
424B5424B5
424B5
2026-05-20
View
424B5424B5
424B5
2026-05-19
View
10-QQuarterly Report
10-Q
2026-05-15
View
8-KCurrent Report
FORM 8-K
2026-05-15
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-30
View
DEF 14AProxy Statement
FORM DEF 14A
2026-04-30
View
8-KCurrent Report
FORM 8-K
2026-04-10
View
424B5424B5
424B5
2026-04-09
View
8-KCurrent Report
FORM 8-K
2026-03-25
View
8-KCurrent Report
FORM 8-K
2026-03-16
View
10-KAnnual Report
10-K
2026-03-13
View
8-KCurrent Report
FORM 8-K
2026-02-12
View
8-KCurrent Report
FORM 8-K
2026-01-28
View
8-KCurrent Report
8-K
2025-11-13
View
Showing 1–15 of 216 filingsForm 4 / 144 hidden· 297 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001477845  |  Exchange: NYSE · Healthcare

Annovis Bio, Inc. (NYSE: ANVS) has submitted 297 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2020. As a Healthcare sector company with CIK 0001477845, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Annovis Bio, Inc.'s most comprehensive regulatory disclosure. The most recent Annovis Bio, Inc. 10-K was filed on 2026-03-13 for fiscal year ending 2026. Historical ANVS 10-K annual reports are available from 2010 through 2026.

Investors researching Annovis Bio, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09

Frequently Asked Questions

ANVS SEC Filings · 8 questions

Annovis Bio, Inc. (ANVS) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 297 filings and access original documents at no cost. Annovis Bio, Inc.'s CIK is 0001477845.

ANVS SEC filingsAnnovis Bio, Inc. SEC documentsfind ANVS 10-K